Clinical Trial

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-04; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2026-02-25
Trial Details
NCT Number NCT06304103
Lead Sponsor Kind Pharmaceuticals LLC
Conditions Myelodysplastic Syndromes
Enrollment 63 participants
Start Date 2025-03-14
Primary Completion 2026-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-27